Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
65.50    0.00 (0.00%)
Bid:
64.00
Ask:
67.00
Spread: 3.00 (4.688%)
Market Cap: £15.96m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

2 Mar 2021 07:00

RNS Number : 7803Q
MyCelx Technologies Corporation
02 March 2021
 

2 March 2021

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside information is now considered to be in the public domain.

 

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and air technology experts, supplying customers with cost-effective, future-proof solutions that optimise production and protect the environment, is pleased to announce a trading update on the Company's operations.

 

MYCELX has made a strong start to the year with two project extensions signed with customers in the Kingdom of Saudi Arabia. These projects confirm that MYCELX's superior solutions continue to support its customers' efforts to optimise production, increase cost savings and improve energy efficiency. During Q1, the Company will commence delivery of the equipment for its third sale to Nigeria.

 

Following product development initiatives in 2020, carried out to enhance its REGEN solution, the Company has secured a paid trial. This will demonstrate REGEN's superior performance over other water treatment offerings for Enhanced Oil Recovery ("EOR") production. The Company has commenced fabrication of this system in Q1 and anticipates that a successful outcome of this trial will lead to heightened interest in the REGEN product offering by leading EOR producers.

 

The value of these project extensions, trial and capital sale amounts to $3.5m in revenue for 2021.

 

As previously reported, the impact of the COVID-19 pandemic and the resulting disruption to its core markets meant that 2020 was an extremely challenging year for the business, with generated revenue of $7.1 million during the year. The Company's strong start to this year demonstrates it has successfully navigated the downturn by focusing on supporting customers, advancing product development initiatives and implementing cost controls. The Company notes the recent increase in activity in core markets, and is well positioned to progress new contracts as the global economy begins to recover.

 

MYCELX also recently announced the sale of its building in Duluth, Georgia, USA, to right-size its office space needs across its main operating locations, as part of the cost reduction program. The sale enables MYCELX to achieve a financial gain of approximately $2.5 million. After the sale closes, the Company will have circa $6 million of cash and cash equivalents on the balance sheet.

 

Commenting on the market update, Connie Mixon, CEO, said:

 

"Following a challenging year, I am pleased to report that we are seeing an increase in activity in the markets in which we operate. This can be seen with the two contract extensions we have signed in Q1 2021, alongside the exciting opportunities arising from the paid trial for REGEN and our development of novel product applications. While we expect it to take time for the wider energy and industrial markets to normalize, we anticipate bidding activity by customers to increase, bolstered by the global economic recovery.

 

The Company continues to benefit from being in a financially robust position, following the cost reduction measures implemented in 2020 and the sale of the building in Duluth, and we look forward to keeping our stakeholders updated on our business progress over the coming months."

 

 

For further information please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Georgina McCooke

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

Notes to Editors

MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the Oil and Gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems and in a virtually fail-safe process.

www.mycelx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSUEFFEFSEED
Date   Source Headline
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address
3rd Jun 20133:19 pmRNSTotal Voting Rights
28th May 20135:02 pmRNSHolding(s) in Company
28th May 20132:54 pmRNSDirector/PDMR Shareholding
24th May 20138:52 amRNSHolding(s) in Company
14th May 20132:14 pmRNSResult of Annual Meeting
14th May 20137:00 amRNSOperational Update & Directorate Change
9th May 20137:00 amRNSExercise of Warrant
23rd Apr 201312:49 pmRNSApplication for Block Admission

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.